Navigation Links
Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting
Date:6/2/2008

ion resistant prostate cancer and bone metastases, and these data encourage further exploration of the ability of tumor antigen release by radiotherapy to serve as an immune-supportive intervention in combination with ipilimumab as a potentially important treatment option for these patients."

The Phase 1/2 trial was conducted to evaluate the safety and preliminary anti-tumor activity of escalating doses of ipilimumab (3, 5 or 10 mg/kg) every three weeks for up to four doses, with and without a single dose of focal radiotherapy administered to target bone lesion(s) prior to the first dose of ipilimumab. The dose escalation portion of the trial enrolled 33 patients with mCRPC and with bone metastases. Additional patients are enrolling in the expansion cohort of 10mg/kg ipilimumab in combination with radiotherapy.

Adverse events related to ipilimumab in this study were generally manageable and consistent with those immune-related adverse events (irAEs) previously reported in other clinical trials of ipilimumab. Grade 3/4 adverse events included diarrhea/colitis (5 patients), rash (1 patient) and elevated liver enzymes (2 patients). No new patterns or frequency of adverse events emerged in patients receiving the combination of ipilimumab and radiotherapy.

About Ipilimumab

Ipilimumab is a fully human antibody that binds to CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), a molecule on T-cells that plays a critical role in regulating natural immune responses. The absence or presence of CTLA- 4 can augment or suppress the immune system's T-cell response in fighting disease. Ipilimumab is designed to block the activity of CTLA-4, thereby sustaining an active immune response in its attack on cancer cells.

Comprehensive Clinical Trial Program for Ipilimumab

Bristol-Myers Squibb Company and Medarex remain committed to the development of ipilimumab. The companies also have ongoing Phase 2 studies in hormone-refractory prostate canc
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. AMT Announces Positive Interim Clinical Data on its Lead Product AMT-011
2. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
3. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
4. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
5. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
6. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
7. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
8. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
9. NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
10. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
11. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 19, 2013 Ellen MacArthur ... kommande tre åren kommer att vara en partner ... cirkulär ekonomi. Efter stiftelsens framgångsrika partnerskap ... Grid, kommer Philips att ansluta sig som partner ... i sin egen verksamhet och stödja stiftelsens arbete ...
(Date:6/19/2013)... , June 19, 2013 The Physician-Patient Alliance ... alarm fatigue. The need to urgently address this ... its Sentinel Event Alert #50 , "Medical device alarm safety ... database, between January 2008 and June 2012, there were 98 ... resulted in death (82%) , 13 resulted in permanent ...
(Date:6/19/2013)... , June 19, 2013   BioCision , ... standardization and handling in many areas of medical ... new patents by the U.S. Patent Office that ... developed to standardize sample handling to ensure the ... in common laboratory procedures. Patent ...
Breaking Medicine Technology:Ellen MacArthur Foundation presenterar Philips som global partner vid det konstituerande internationella toppmötet om cirkulär ekonomi 2Ellen MacArthur Foundation presenterar Philips som global partner vid det konstituerande internationella toppmötet om cirkulär ekonomi 3Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3BioCision Announces Two New U.S. Patents for Thermo-Conductive Products that Standardize Sample Handling in Laboratory Research 2
... April 14, 2011 /PRNewswire-Asia/ -- Winner Medical Group Inc. ... Company") a leading manufacturer of medical dressings, medical disposables ... in China, today announced that the Company will attend ... Exhibition to be held in the Shenzhen Convention and ...
... Reportlinker.com announces that a new market research ... Endometrial Cancer Therapeutics - Pipeline Assessment and ... http://www.reportlinker.com/p0479825/Endometrial-Cancer-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html Endometrial Cancer Therapeutics - ... Summary GlobalData, the ...
Cached Medicine Technology:Winner Medical to Attend 65th CMEF Spring11 Exhibition in Shenzhen 2Winner Medical to Attend 65th CMEF Spring11 Exhibition in Shenzhen 3Winner Medical to Attend 65th CMEF Spring11 Exhibition in Shenzhen 4Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 7Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 8Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 9Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 10
(Date:6/19/2013)... TX (PRWEB) June 19, 2013 Chrysler made ... concerning a recall of 2.7 million Jeeps. The Jeep models ... 2002-2007 Jeep Liberty, which according to the NHTSA are vulnerable ... gas tanks in these models are rear-mounted and have been ... agency findings show the Grand Cherokee with 32 rear-end crashes, ...
(Date:6/19/2013)... June 19, 2013 Amber Roberson ... RWI Benefits, LLC, Native Care Health, LLC and ... of Health Underwriters’ (NAHU) new professional development course ... (PPACA). This continuing education course for agents has ... will receive eleven education credits from the Missouri ...
(Date:6/19/2013)... New York, New York (PRWEB) June 19, 2013 ... involving pancreatitis and pancreatic cancer continue to mount in ... the U.S. Food & Drug Administration (FDA) recently held ... other diabetes drugs known as incretin mimetics. According ... may seek additional data from the makers of Januvia ...
(Date:6/19/2013)... 2013 The Journal of Parasitology – ... computer software, it creates questions of ethics. For scientific ... an already published case shows, scientific publications need clear ... The Journal of Parasitology features a commentary ... 2004 article published in the Journal of the New ...
(Date:6/19/2013)... led by researchers at The University of Texas MD ... show remarkable promise for the treatment of relapsed or ... interim findings of the 18-center Phase 2 study were ... Medicine . Previous interim findings were presented in December ... Meeting and Exposition. , Unprecedented results, fewer ...
Breaking Medicine News(10 mins):Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 2Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 3Health News:RWI Benefits, LLC Becomes PPACA Certified 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2
... it has been found that students who are well fed ... ,The study was done at Cornell's Early Childhood Centre. ... development especially in reading. ,This phenomenon is ... do not have enough to eat due to poverty in ...
... treatment medicine acclaimed the world over Tamiflu now will be ... firm Roche to make a generic version of its anti-flu ... The company is Hetero Drugs. ,The drug is ... future pandemic of bird flu in humans. ,The Swiss drugs ...
... Indian American Scientist Dr. Henry Daniell has produced a ... plant. The new gene transfer technique to tobacco plants ... symptoms and rashes involved in conventional anthrax vaccine fermentation ... of 360 million doses in one acre of tobacco ...
... company that extracts chemicals from plants, plans to use used ... drug that treat bird flu.// ,The trees contain ... Biolyse said today in a statement. The acid is used ... star anise trees in China, Biolyse said. ,Tamiflu ...
... larger brains have better intellect, according to McMaster University’s ... said that there were differences between women and men. ... Brain also said, said that in women, verbal intelligence ... of the verbal IQ score. ,However, ...
... of the rising rates of infection with C.difficile among ... mutation of the microorganism into a more virulent form.// ... manifest in individuals with resistance to antibiotics. ... non-hospitalized patients has created much panic among the scientific ...
Cached Medicine News:Health News:Christmas trees to yield key Tamiflu ingredient 2Health News:Rising Rates Of C.Difficile Infection Among Non-Hospitalized Patients 2
The Advia 60 is designed to deliver powerful performance in a small package....
AcT 5diff OV enables low-volume labs to advance to 5-part differential analysis at an affordable price. This analyzer delivers accurate test results and a user-friendly software interface in a compac...
... three-dimensional VCS technology, providing ... efficiency in white cell ... With its reputation for ... is an affordable solution ...
... 750 analyzer is equipped with ... random access capabilities. These advancements ... pre-sorting of samples and speed ... system, you can improve overall ...
Medicine Products: